US Patent

US7569610 — Modified release formulations of a bupropion salt

Method of Use · Assigned to Biovail Laboratories International SRL · Expires 2026-06-27 · 0y remaining

Vulnerability score 85/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects modified-release formulations of bupropion hydrobromide, specifically modified-release tablets, for use in treating a condition.

USPTO Abstract

The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.

Drugs covered by this patent

bupropion-hydrobromide (BUPROPION HYDROBROMIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-997`	—	bupropion-hydrobromide
`U-997`	—	bupropion-hydrobromide
`U-997`	—	bupropion-hydrobromide

Patent Metadata

Patent number: US7569610
Jurisdiction: US
Classification: Method of Use
Expires: 2026-06-27
Drug substance claim: No
Drug product claim: No
Assignee: Biovail Laboratories International SRL
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.